•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
Annovis Announces Pricing of $21.0 Million Public Offering
Annovis Announces Launch of Proposed Public Offering
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Annovis to Attend the CTAD 2026 with Three Presentations
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA
Annovis to Host Corporate Update Webinar on September 2, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Bio Regains NYSE Listing Compliance
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026